Compare BridgeBio Pharma Inc (BBIO) vs Dow Jones Industrial Average ETF (DIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Dow Jones Industrial Average ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Dow Jones Industrial Average ETF trades at $537.27. Which is the better fit depends on your goals.
| BBIO | DIA | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | — |
52-Week High | $90.17 | $542.79 |
52-Week Low | $47.29 | $444.64 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
DIA trades at $539.70, up 0.28% today, with a bullish technical signal from moving averages and key support at $538. Recent dividends include $1.41 paid in July 2026, reflecting income stability. The stock benefits from broad market momentum, as highlighted by ETF inflows into U.S. equities (ETF Trends, August 7, 2026).
Outlook remains positive due to technical strength and defensive positioning in blue-chip ETFs, but overbought RSI levels near 86 suggest short-term caution. Risks include market volatility from Fed policy and geopolitical tensions, though institutional support provides a cushion for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →
